Status:
RECRUITING
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
Lead Sponsor:
Huihan Wang
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Acute myeloid leukemia (AML) is a disease affecting older adults, although optimal strategies for treating such patients remain unclear. This prospective phase II, openlabel, multicenter study was des...
Detailed Description
Acute myeloid leukemia (AML) is one of the most common hematologic malignancies and affects older adults. The median age at diagnosis is 67 years. As the elderly increasingly account for a greater pop...
Eligibility Criteria
Inclusion
- Age 60 or above, male or female;
- Acute Myeloid Leukemia (non-M3) diagnosed according to the 2008 World Health Organization (WHO) diagnostic criteria for myeloid malignancies;
- Newly diagnosed, no treatment for anti-leukemia;
- The Eastern Cooperative Oncology Group（ECOG） status score is 0 to 3 points;
- Expected survival time ≥ 3 months;
- No serious heart, lung, liver or kidney disease;
- History of no thromboembolism
- Ability to understand and be willing to sign the informed consent form of this trial.
Exclusion
Key Trial Info
Start Date :
January 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 21 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05258799
Start Date
January 21 2022
End Date
January 21 2026
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ShengJing Hospital of China Medical University
Shenyang, Liaoning, China, 110004